• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Boston Scientific to buy BridgePoint Medical

Boston Scientific to buy BridgePoint Medical

September 19, 2012 By MassDevice staff

BridgePoint Medical

Boston Scientific (NYSE:BSX) said it agreed to buy BridgePoint Medical for an undisclosed amount, adding the Minneapolis-based medical device company’s technology for treating blocked blood vessels in the heart to its stable of interventional cardiology tools.

BridgePoint’s technology is designed to allow cardiologists to treat coronary chronic total occlusions by threading a catheter guidewire across the blockage. Its CrossBoss CTO-crossing catheter and Stingray CTO re-entry system is cleared for sale in the U.S. and Europe, according to a press release.

BridgePoint has also developed similar technology for treating blocked blood vessels in the legs, the TruePath and OffRoad devices, which is not yet cleared for use in the U.S.

Boston Scientific said the deal, expected to close during the 4th quarter, isn’t likely to affect earnings this year or in 2013 and be "modestly accretive" after that.

Sign up to get our free newsletters delivered straight to your inbox

"We look forward to welcoming the outstanding team at BridgePoint Medical to Boston Scientific," interim BSX CEO Hank Kucheman said in prepared remarks. "The acquisition of BridgePoint Medical is expected to build upon our rich product portfolio in cardiology and represents an important part of our growth strategy in this critical market. We believe the BridgePoint coronary devices will provide the Boston Scientific interventional cardiology business a dedicated CTO solution while the Boston Scientific peripheral intervention business offers the TruePath CTO device and OffRoad CTO device. This will position the company as the leader in CTO technologies across the cardiovascular system."

The link between BridgePoint and Boston Scientific runs deep. BridgePoint CEO Denis Harrington spent 18 years at BSX, rising to head of sales for its cardiovascular and CRM business before taking the corner office at BridgePoint, and co-founder & COO Chad Kugler got his start as an engineer at BSX, according to BridgePoint’s website. Board member Mike Berman is also a Boston Scientific veteran, according to the site.

Filed Under: Catheters, Mergers & Acquisitions, News Well, Stents Tagged With: Boston Scientific, BridgePoint Medical Inc.

More recent news

  • Cooper Companies continues to see activist pressure to sell divisions, replace CEO
  • Cordis earns FDA nod for Selution SLR drug-eluting balloon
  • Siemens Healthineers links with Novo to advance liver fibrosis blood test
  • GE HealthCare rolls out AI software for predicting care bottlenecks
  • Wandercraft’s self-balancing Eve exoskeleton begins US launch

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy